All In Biotech

Drug Trial Radar · NCT03481634

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Jan 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 566 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

566

Actual

Start

Jul 23, 2018

Primary completion

Nov 11, 2020

Study completion Oct 18, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).

Conditions

  • Diabetic Macular Edema

Interventions

  • BrolucizumabDrug

    Intravitreal injection

  • AfliberceptDrug

    Intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52Time frame: Baseline, Week 52

Locations

116 sites in 14 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    La Jolla, California

  • Novartis Investigative Site

    Mountain View, California

  • Novartis Investigative Site

    Santa Barbara, California

  • Novartis Investigative Site

    Colorado Springs, Colorado

  • Novartis Investigative Site

    Danbury, Connecticut

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Pensacola, Florida

  • Novartis Investigative Site

    Stuart, Florida

  • Novartis Investigative Site

    ‘Aiea, Hawaii

  • Novartis Investigative Site

    Urbana, Illinois

  • Novartis Investigative Site

    Wheaton, Illinois

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    New Albany, Indiana

  • Novartis Investigative Site

    Leawood, Kansas

  • Novartis Investigative Site

    Lenexa, Kansas

  • Novartis Investigative Site

    Paducah, Kentucky

  • Novartis Investigative Site

    Springfield, Massachusetts

  • Novartis Investigative Site

    Stoneham, Massachusetts

  • Novartis Investigative Site

    Reno, Nevada

  • Novartis Investigative Site

    Cincinnati, Ohio

  • Novartis Investigative Site

    Cleveland, Ohio

  • Novartis Investigative Site

    Cleveland, Ohio

  • Novartis Investigative Site

    Kingston, Pennsylvania

  • Novartis Investigative Site

    Philadelphia, Pennsylvania

  • Novartis Investigative Site

    Memphis, Tennessee

  • Novartis Investigative Site

    Nashville, Tennessee

  • Novartis Investigative Site

    Austin, Texas

  • Novartis Investigative Site

    Austin, Texas

  • Novartis Investigative Site

    Austin, Texas

  • Novartis Investigative Site

    Bellaire, Texas

  • Novartis Investigative Site

    Harlingen, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Tyler, Texas

  • Novartis Investigative Site

    Silverdale, Washington

  • Novartis Investigative Site

    Spokane, Washington

  • Novartis Investigative Site

    Madison, Wisconsin

  • Novartis Investigative Site

    CABA, Argentina

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.